Shares of Edwards Lifesciences Corp (NYSE:EW) were up 1.3% on Tuesday . The stock traded as high as $165.97 and last traded at $167.07. Approximately 80,711 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 1,072,208 shares. The stock had previously closed at $164.85.

Several analysts recently weighed in on EW shares. Guggenheim reiterated a “buy” rating and issued a $170.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $168.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a report on Saturday, July 14th. ValuEngine upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 12th. Finally, SunTrust Banks cut their price target on shares of Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus price target of $152.45.

The firm has a market cap of $32.18 billion, a P/E ratio of 43.04, a price-to-earnings-growth ratio of 2.12 and a beta of 0.57. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 26th. The medical research company reported $1.24 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The firm had revenue of $972.00 million for the quarter, compared to analysts’ expectations of $968.32 million. During the same quarter in the previous year, the business posted $1.08 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. equities analysts forecast that Edwards Lifesciences Corp will post 4.67 earnings per share for the current year.

In other news, VP Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $144.16, for a total value of $792,880.00. Following the completion of the transaction, the vice president now owns 25,490 shares of the company’s stock, valued at approximately $3,674,638.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Larry L. Wood sold 6,300 shares of Edwards Lifesciences stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $146.95, for a total value of $925,785.00. Following the completion of the transaction, the vice president now directly owns 121,950 shares of the company’s stock, valued at approximately $17,920,552.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 183,811 shares of company stock valued at $26,346,476. 1.84% of the stock is owned by insiders.

Large investors have recently modified their holdings of the business. FMR LLC boosted its stake in Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock worth $977,456,000 after purchasing an additional 1,663,511 shares during the period. WCM Investment Management CA boosted its stake in Edwards Lifesciences by 19,310.8% in the 2nd quarter. WCM Investment Management CA now owns 455,377 shares of the medical research company’s stock worth $66,290,000 after purchasing an additional 453,031 shares during the period. Morgan Stanley boosted its stake in Edwards Lifesciences by 38.4% in the 2nd quarter. Morgan Stanley now owns 1,329,458 shares of the medical research company’s stock worth $193,531,000 after purchasing an additional 369,027 shares during the period. First Trust Advisors LP boosted its stake in Edwards Lifesciences by 633.6% in the 2nd quarter. First Trust Advisors LP now owns 364,884 shares of the medical research company’s stock worth $53,116,000 after purchasing an additional 315,144 shares during the period. Finally, Voya Investment Management LLC boosted its stake in Edwards Lifesciences by 47.9% in the 2nd quarter. Voya Investment Management LLC now owns 911,238 shares of the medical research company’s stock worth $132,649,000 after purchasing an additional 295,113 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Stock Symbol

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.